Emergent Biosolutions Inc. (NYSE:EBS) Receives Consensus Rating of “Hold” from Brokerages

Posted by Stanley Muller on Jun 3rd, 2026

Emergent Biosolutions Inc. (NYSE:EBS – Get Free Report) has earned an average rating of “Hold” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $12.00.

A number of equities analysts have issued reports on EBS shares. Wall Street Zen downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. HC Wainwright dropped their target price on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday. Weiss Ratings lowered Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday.

Read Our Latest Stock Report on EBS

Emergent Biosolutions Stock Down 9.4%

EBS stock traded down $0.86 during midday trading on Tuesday, reaching $8.27. 850,701 shares of the company’s stock traded hands, compared to its average volume of 751,814. Emergent Biosolutions has a 52 week low of $5.61 and a 52 week high of $14.06. The company has a market cap of $426.47 million, a price-to-earnings ratio of -29.68 and a beta of 2.33. The firm’s fifty day moving average price is $8.40 and its 200-day moving average price is $10.10. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The firm had revenue of $156.10 million during the quarter, compared to analysts’ expectations of $145.00 million.

Insider Activity

In related news, Director Keith Katkin sold 15,481 shares of the business’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $8.28, for a total transaction of $128,182.68. Following the transaction, the director directly owned 96,294 shares in the company, valued at approximately $797,314.32. The trade was a 13.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sujata Tyagi Dayal sold 13,761 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $115,592.40. Following the completion of the sale, the director directly owned 100,563 shares of the company’s stock, valued at $844,729.20. The trade was a 12.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,925 shares of company stock valued at $518,312 over the last ninety days. Company insiders own 6.00% of the company’s stock.

Institutional Trading of Emergent Biosolutions

A number of institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC raised its stake in Emergent Biosolutions by 68.9% in the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after acquiring an additional 1,020,582 shares during the period. Jain Global LLC bought a new position in Emergent Biosolutions in the 3rd quarter worth approximately $4,487,000. Dimensional Fund Advisors LP boosted its holdings in Emergent Biosolutions by 22.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after buying an additional 504,553 shares during the period. HRT Financial LP purchased a new position in Emergent Biosolutions in the 4th quarter valued at approximately $3,853,000. Finally, Jump Financial LLC raised its holdings in Emergent Biosolutions by 468.4% during the 3rd quarter. Jump Financial LLC now owns 314,000 shares of the biopharmaceutical company’s stock valued at $2,769,000 after acquiring an additional 258,757 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent Biosolutions

(Get Free Report)

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.